Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

A charity boss who struggled for years to shed pounds despite having undergone surgery has hailed weight-loss jabs as ...

As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...